This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kakoki, M. Articles by Omata, M. Search for Related Content PubMed PubMed Citation Articles by Kakoki, M. Articles by Omata, M. Related Collections Risk Factors Endothelium/vascular type/nitric oxide

(Circulation. 1999;99:1242-1248.)
© 1999 American Heart Association, Inc.

Basic Science Reports

Effects of Hypertension, Diabetes Mellitus, and Hypercholesterolemia on Endothelin Type B Receptor–Mediated Nitric Oxide Release From Rat Kidney

Masao Kakoki, MD; Yasunobu Hirata, MD; Hiroshi Hayakawa, MD; Akihiro Tojo, MD; Daisuke Nagata, MD; Etsu Suzuki, MD; Kenjiro Kimura, MD; Atsuo Goto, MD; Kazuya Kikuchi, PhD; Tetsuo Nagano, PhD; Masao Omata, MD

From the Second Department of Internal Medicine, Faculty of Medicine (M.K., Y.H., H.H., A.T., D.N., E.S., K. Kimura, A.G., M.O.), and Faculty of Pharmaceutical Sciences (K. Kikuchi, T.N.), University of Tokyo, Tokyo, Japan.

Correspondence to Yasunobu Hirata, MD, The Second Department of Internal Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan. E-mail hirata-2im{at}h.u-tokyo.ac.jp

Background—Although endothelin-1 is a potent vasoconstrictor peptide, stimulation of endothelin type B receptor (ETBR) causes bidirectional changes in vascular tone, ie, vasodilation and vasoconstriction. Roles of ETBR in pathological conditions are largely unknown.

Methods and Results—We studied the effect of BQ-3020, a highly selective ETBR agonist, on renal vascular resistance and nitric oxide (NO) release in the isolated, perfused kidney of rats with hypertension, diabetes mellitus, and hypercholesterolemia. Immunohistochemistry of endothelial NO synthase and ETBR was also examined. Infusion of BQ-3020 at concentrations of 10^-10 mol/L reduced renal perfusion pressure in Dahl salt-resistant (R) rats but increased renal perfusion pressure in Dahl salt-sensitive (S) rats (10^-10 mol/L: -10.3±0.6% versus 11.2±1.5%, R versus S; P<0.01). BQ-3020 caused a dose-dependent release of NO in both R and S rats, although the level of NO release in S rats was lower, as detected by chemiluminescence (10^-10 mol/L: 10.7±0.7 versus 3.1±0.4 fmol/min per gram of kidney, R versus S; P<0.01). Similar effects of BQ-3020 were observed in streptozotocin-induced diabetic rats and diet-induced hypercholesterolemic rats. Expression of endothelial NO synthase decreased in S rats but not in diabetic or hypercholesterolemic rats. In contrast, expression of ETBR in the endothelium was decreased in all 3 disease models compared with that in the vascular smooth muscle cell.

Conclusions—These results suggest that impaired NO release in response to stimulation of ETBR is due, at least in part, to a decrease in endothelial ETBR and may play a role in vascular dysfunction usually associated with arteriosclerosis-related diseases.

Key Words: immunohistochemistry • diabetes mellitus • hypertension • hypercholesterolemia • angiotensin

This article has been cited by other articles:

				M. Kakoki, H.-S. Kim, C.-J. S. Edgell, N. Maeda, O. Smithies, and D. L. Mattson Amino acids as modulators of endothelium-derived nitric oxide Am J Physiol Renal Physiol, August 1, 2006; 291(2): F297 - F304. [Abstract] [Full Text] [PDF]

				A. Tojo, M. L. Onozato, N. Kobayashi, A. Goto, H. Matsuoka, and T. Fujita Angiotensin II and Oxidative Stress in Dahl Salt-Sensitive Rat With Heart Failure Hypertension, December 1, 2002; 40(6): 834 - 839. [Abstract] [Full Text] [PDF]

				T. K. A. WIEREMA, A. J. H. M. HOUBEN, A. A. KROON, D. KOSTER, K. V. D. ZANDER, J. M. A. V. ENGELSHOVEN, and P. W. D. LEEUW Nitric Oxide Dependence of Renal Blood Flow in Patients with Renal Artery Stenosis J. Am. Soc. Nephrol., September 1, 2001; 12(9): 1836 - 1843. [Abstract] [Full Text] [PDF]

				C. B. Taner, S. R. Severson, P. J. M. Best, A. Lerman, and V. M. Miller Treatment with endothelin-receptor antagonists increases NOS activity in hypercholesterolemia J Appl Physiol, March 1, 2001; 90(3): 816 - 820. [Abstract] [Full Text] [PDF]

				F. Mori, G. L. King, A. C. Clermont, D. K. Bursell, and S.-E. Bursell Endothelin-3 Regulation of Retinal Hemodynamics in Nondiabetic and Diabetic Rats Invest. Ophthalmol. Vis. Sci., November 1, 2000; 41(12): 3955 - 3962. [Abstract] [Full Text]

				M. Barton, L. V. d'Uscio, Y. Hirata, M. Kakoki, H. Hayakawa, A. Tojo, D. Nagata, E. Suzuki, K. Kimura, A. Goto, et al. Hypertension, Diabetes Mellitus, Hypercholesterolemia, and Endothelin B Receptor-Mediated Renal Nitric Oxide Release Response Circulation, June 13, 2000; 101 (23): e228 - e229. [Full Text] [PDF]

				S. Dhein, S. Hochreuther, C. a. d. Spring, K. Bollig, C. Hufnagel, and M. Raschack Long-Term Effects of the EndothelinA Receptor Antagonist LU 135252 and the Angiotensin-Converting Enzyme Inhibitor Trandolapril on Diabetic Angiopathy and Nephropathy in a Chronic Type I Diabetes Mellitus Rat Model J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 351 - 359. [Abstract] [Full Text]